IDEAYA Biosciences share price logo

IDEAYA Biosciences

NASDAQ: IDYA

Mid Cap

$39.67

+0.56

(+1.43%)

as on

IDEAYA Biosciences Stock Performance

as on August 22, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $39.31
    $40.56
    downward going graph

    0.91%

    Downside

    2.24%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $23.23
    $40.58
    downward going graph

    41.44%

    Downside

    2.29%

    Upside

    downward going graph

IDEAYA Biosciences share price movements today

Previous Close
$39.11
Open
$39.31
Volume
691.9K
Market Cap
$3.5B
Day's Low - High
$39.31 - $40.56
52 Week Low - High
$23.23 - $40.58

IDEAYA Biosciences Historical Returns

1 Month Return
+ 0.81 %
3 Month Return
+ 28.68 %
1 Year Return
+ 49.2 %
3 Year Return
+ 46.02 %
5 Year Return
+ 54.34 %

IDEAYA Biosciences Stock Fundamentals & Key Indicators

Check IDEAYA Biosciences market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$3.5B

EPS (TTM)

-4.6112

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-214.2M

Revenue (TTM)

234.1M

Profit Margin

-74.75%

Return On Equity TTM

-16.22%

IDEAYA Biosciences vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of IDEAYA Biosciences with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
IDEAYA Biosciences image
IDEAYA Biosciences
BUY$3.5B54.34%NA-74.75%NA
Revolution Medicines image
Revolution Medicines
BUY$43.7B669.3%NA0.00%NA
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
BUY$128.2B154.86%29.8286.04%NA
Moderna image
Moderna
BUY$25.3B-84.24%-7.98-12.57%NA
Regeneron image
Regeneron
BUY$82.7B24.1%19.2484.86%0.44999999999999996%

Stock Returns calculator for IDEAYA Biosciences Stock including INR - Dollar returns

The IDEAYA Biosciences stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

IDEAYA Biosciences investment value today

Current value as on today

₹1,78,694

Returns

₹78,694

(+78.69%)

Returns from IDEAYA Biosciences Stock

₹63,050 (+63.05%)

Dollar Impact

₹15,644 (+15.64%)

Analyst Recommendation on IDEAYA Biosciences Stock

Based on 11 analysts

BUY

90.91%

Buy

9.09%

Hold

0.00%

Sell

Based on 11 analysts, 90.9090909090909% of analysts recommend a 'BUY' rating for IDEAYA Biosciences. Average target price of $52.15

IDEAYA Biosciences Share Price Target

Get share price movements and forecasts by analysts on IDEAYA Biosciences.

What analysts predicted

23.93%UPSIDE

Target Price

$52.15

Current Price

$39.67

Analyzed by

11 Analysts

Target

$52.15

IDEAYA Biosciences target price $52.15, a slight upside of 23.93% compared to current price of $39.67. According to 11 analysts rating.

Indian Investors' Interest in IDEAYA Biosciences Stock

Search interest for IDEAYA Biosciences Stock has decreased by -27% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-27% versus previous 30 day period

IDEAYA Biosciences Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
-
-
-
7
-
-
207
10
6
8
Gross Profit
-1
-1
-1
6
-70
-74
124
-75
-89
8
Operating Income
-51
-64
-66
-144
-84
-88
108
-94
-108
-122
EBITDA
-51
-51
-50
-129
-83
-87
109
-93
-107
-121
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
1
1
1
0
1
1
1
1
1
1
Income Before Tax
-39
-52
-51
-130
-72
-77
119
-83
-98
-112
Income Tax Expense
-1
-1
-
-
-
-
-
-
-
-
Net Income
-39
-52
-51
-130
-72
-77
119
-83
-98
-112
Net Profit Margin
0.00%
0.00%
0.00%
-1861.60%
0.00%
0.00%
57.37%
-765.66%
-1502.12%
-1269.64%

IDEAYA Biosciences Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
-
-
19
27
50
23
7
218
Gross Profit
0
0
-1
19
27
50
19
3
-95
Operating Income
-14
-36
-44
-35
-50
-62
-134
-326
-159
EBITDA
-11
-33
-43
-33
-48
-60
-108
-270
-154
Interest Expense
-
-
-
0
0
3
21
-
-
Depreciation
0
0
1
1
1
2
4
3
4
Income Before Tax
-11
-34
-41
-34
-49
-58
-112
-274
-113
Income Tax Expense
0
2
-3
-2
-2
-3
3
-
-
Net Income
-11
-34
-38
-32
-47
-54
-112
-274
-113
Net Profit Margin
0.00%
0.00%
0.00%
-165.14%
-170.11%
-107.61%
-483.05%
-3921.10%
-51.99%

IDEAYA Biosciences Quarterly Cash Flow

All numbers in Millions USD

Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-52
-51
-130
-72
-77
119
-83
-98
-210
Operating Cash Flow
-32
-49
-121
-60
-62
142
-90
-75
-163
Investing Cash Flow
68
-20
-197
79
45
41
-97
118
-36
Financing Cash Flow
39
286
2
26
1
0
2
1
360
Change in Cash
74
217
-316
45
-15
184
-186
44
160

IDEAYA Biosciences Annual Cash Flow

All numbers in Millions USD

Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-34
-41
-34
-49
-58
-112
-274
-113
Operating Cash Flow
-27
-39
55
-55
-87
-115
-247
-71
Investing Cash Flow
-63
2
-146
-69
-33
-158
-502
69
Financing Cash Flow
105
50
128
145
97
362
677
29
Change in Cash
14
13
37
20
-23
89
-72
28

Mutual Funds that own IDEAYA Biosciences Stock

Check out the Mutual Funds with significant holdings in IDEAYA Biosciences.

Funds
Holdings
Shares Held
Fidelity Mt. Vernon Street Trust
6.819596%
6580194
SMALLCAP World Fund Inc
4.854862%
4684432
VANGUARD INDEX FUNDS
3.778242%
3645607
JANUS INVESTMENT FUND
2.263309%
2183856
Federated Hermes Equity Funds
1.464072%
1412676
See all

Global Institutional Holdings in IDEAYA Biosciences

Funds
Holdings
Vanguard
5.02%
iShares
4.51%
Felix Baker
4.09%
SPDR
2.81%
James E. Flynn
1.59%
See all

IDEAYA Biosciences News & Key Events

    Insights on IDEAYA Biosciences

    Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

    • imgPOSITIVE IMPACT

      Price Rise

      img

      In the last 7 days, IDYA stock has moved up by 9.3%

    • imgPOSITIVE IMPACT

      Revenue Rich

      img

      Revenue is up for the last 2 quarters, 6.56M → 8.85M (in $), with an average increase of 25.9% per quarter

    • imgNO EFFECT

      Against Peers

      img

      In the last 1 year, Revolution Medicines, Inc. Common Stock has given 466.0% return, outperforming this stock by 408.1%

    • imgNO EFFECT

      Against Peers

      img

      In the last 3 years, Revolution Medicines, Inc. Common Stock has given 570.7% return, outperforming this stock by 529.6%

    • imgNEGATIVE IMPACT

      Profit Down

      img

      Netprofit is down for the last 4 quarters, 119.24M → -112.45M (in $), with an average decrease of 67.4% per quarter

    About IDEAYA Biosciences

    IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings. The company also offers IDE849, a DLL3 antibody drug conjugate inhibitor for the treatment of SCLC and neuroendocrine carcinomas; IDE034, a B7H3/PTK7 topo-I-payload bispecific BsADC; IDE161, a poly ADP-ribose glycohydrolase inhibitor; IDE705 (GSK101), a Poly Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other mutations associated with HRD; IDE397, a MAT2A inhibitor for MTAP-deleted tumors; IDE892, a PRMT5 inhibitor; IDE574 selectively inhibits KAT6/7 and is in Phase 1 dose escalation trial for patients with breast, lung, prostate, and colorectal cancers; IDE275 oral small molecule inhibitor of the helicase domain of the Werner protein (WRN) and is in a Phase 1 clinical trial. In addition, the company offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Gilead Sciences, Inc., Novartis, Biocytogen, Cancer Research UK, the University of Manchester, Jiangsu Hengrui Pharmaceuticals Co., Ltd., and Les Laboratoires Servie. It also has a clinical collaboration agreement with AstraZeneca plc to evaluate IDE849, an antibody-drug conjugate; and clinical collaboration with Roche to evaluate IDE892, IDEAYA's potential best-in-class Phase 1 MTA-cooperative PRMT5 inhibitor, in combination with RG6505, Roche's Phase 1 pan-R
    OrganisationIDEAYA Biosciences
    Headquarters5000 Shoreline Court, South San Francisco, CA, United States, 94080
    IndustryBiotechnology
    CEOMr. Yujiro S. Hata
    E-voting on sharesClick here to vote

    Key Management of IDEAYA Biosciences

    Name

    Title

    Mr. Andres Ruiz Briseno CPA

    Chief Accounting Officer

    Mr. Douglas B. Snyder

    Chief Legal Officer

    Dr. Darrin M. Beaupre M.D., Ph.D.

    Chief Medical Officer

    Mr. Yujiro S. Hata

    Founder, President, CEO & Chairman

    Dr. Michael A. White Ph.D.

    Chief Scientific Officer

    Dr. Paul A. Barsanti Ph.D.

    Chief Technology Officer

    Ms. Francine Zelaya

    Senior VP & Head of Human Resources

    Mr. Mick O'Quigley

    Senior Vice President of Medical Writing & Project Management

    Mr. Daniel A. Simon

    Chief Business Officer

    Dr. Joshua Bleharski M.B.A., Ph.D.

    Chief Financial Officer

    FAQs

    What is IDEAYA Biosciences share price today?

    IDEAYA Biosciences share price today is $39.67 as on at the close of the market. IDEAYA Biosciences share today touched a day high of $40.56 and a low of $39.31.

    What is the 52 week high and 52 week low for IDEAYA Biosciences share?

    IDEAYA Biosciences share touched a 52 week high of $40.58 on and a 52 week low of $23.23 on . IDEAYA Biosciences stock price today i.e. is closed at $39.67,which is 2.24% down from its 52 week high and 70.77% up from its 52 week low.

    What is IDEAYA Biosciences's market capitalisation today?

    IDEAYA Biosciences market capitalisation is $0.00T as on .

    How to invest in IDEAYA Biosciences Stock (IDYA) from India?

    1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
    2. Step 2: Search for IDEAYA Biosciences on INDmoney app. Click on Buy button. You can invest as low as $1.5 in IDEAYA Biosciences Shares that will get you 0.0378 shares as per IDEAYA Biosciences share price of $39.67 per share as on August 22, 2026 at 8:45 am IST.

    What is the minimum amount required to buy IDEAYA Biosciences Stock (IDYA) from India?

    Indian investors can start investing in IDEAYA Biosciences (IDYA) shares with as little as ₹95.71 or $1 (as of ) using the INDmoney app.
    For example: If you want to invest $10 or ₹957.10 in IDEAYA Biosciences stock (as per the Rupee-Dollar exchange rate as on ). Based on IDEAYA Biosciences share’s latest price of $39.67 as on August 22, 2026 at 8:45 am IST, you will get 0.2521 shares of IDEAYA Biosciences. Learn more about fractional shares .

    What are the returns that IDEAYA Biosciences has given to Indian investors in the last 5 years?

    IDEAYA Biosciences stock has given 54.34% share price returns and 29.17% dollar appreciation to an Indian investor in the last 5 years.
    Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?